William H. Sauer, MD, FHRS, CCDS, of Brigham and Women's Hospital is joined by guests David Chiang, MD, PhD, and Sunil Kapur MD, of Brigham and Women's Hospital to discuss (RAPID): A Multicentre, Randomised Trial. Etripamil is a fast-acting, intranasally administered calcium-channel blocker in development for ondemand therapy outside a health-care setting for paroxysmal supraventricular tachycardia. The authors of this randomized trial evaluated the efficacy and safety of etripamil 70 mg nasal spray using a symptom-prompted, repeat-dose regimen for acute conversion of atrioventricular-nodal-dependent paroxysmal supraventricular tachycardia to sinus rhythm within 30 min.

https://www.hrsonline.org/education/TheLead

Host Disclosure(s):

W. Sauer: Honoraria/Speaking/Consulting Fee: Biotronik, Biosense Webster, Inc., Abbott, Boston Scientific; Research (Contracted Grants for PIs Named Investigators Only): Medtronic

Contributor Disclosure(s):

D. Chiang: No relevant financial relationships with ineligible companies to disclose.

S. Kapur: Honoraria/Speaking/Consulting Fee: Biotronik, Abbott, Medtronic, Inc, Novartis